Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Alpo Vuorio and Petri Kovanen.
Alpo Vuorio
Connection Strength
13.917
Petri Kovanen
  1. Mucormycosis and glucose-regulated protein 78 in COVID-19: Amenable to statin treatment? J Intern Med. 2021 10; 290(4):931-933.
    View in: PubMed
    Score: 0.960
  2. Patients with familial hypercholesterolemia and COVID-19: Efficient and ongoing cholesterol lowering is paramount for the prevention of acute myocardial infarction. Am J Prev Cardiol. 2021 Sep; 7:100224.
    View in: PubMed
    Score: 0.957
  3. Comment on: "Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry". Drugs. 2021 06; 81(9):1125-1127.
    View in: PubMed
    Score: 0.948
  4. Elevated Lipoprotein(a) and Cerebral Venous Sinus Thrombosis in COVID-19. J Stroke Cerebrovasc Dis. 2021 10; 30(10):105865.
    View in: PubMed
    Score: 0.944
  5. Familial hypercholesterolemia and statins in the COVID-19 era: Mitigating the risk of ischemic stroke. eNeurologicalSci. 2021 Jun; 23:100344.
    View in: PubMed
    Score: 0.942
  6. Hospitalized Children With Familial Hypercholesterolemia and COVID-19: A Case for Preventive Anticoagulation. Front Cardiovasc Med. 2021; 8:657719.
    View in: PubMed
    Score: 0.941
  7. Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19. J Clin Lipidol. 2021 Mar-Apr; 15(2):379-380.
    View in: PubMed
    Score: 0.932
  8. Familial hypercholesterolaemia and COVID-19: A two-hit scenario for endothelial dysfunction amenable to treatment. Atherosclerosis. 2021 03; 320:53-60.
    View in: PubMed
    Score: 0.926
  9. Statins as Adjuvant Therapy for COVID-19 to Calm the Stormy Immunothrombosis and Beyond. Front Pharmacol. 2020; 11:579548.
    View in: PubMed
    Score: 0.925
  10. PCSK9 inhibitors for COVID-19: an opportunity to enhance the antiviral action of interferon in patients with hypercholesterolaemia. J Intern Med. 2021 05; 289(5):749-751.
    View in: PubMed
    Score: 0.919
  11. Prevention of endothelial dysfunction and thrombotic events in COVID-19 patients with familial hypercholesterolemia. J Clin Lipidol. 2020 Sep - Oct; 14(5):617-618.
    View in: PubMed
    Score: 0.887
  12. Familial hypercholesterolaemia and COVID-19: triggering of increased sustained cardiovascular risk. J Intern Med. 2020 06; 287(6):746-747.
    View in: PubMed
    Score: 0.878
  13. Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia. Atherosclerosis. 2019 02; 281:25-30.
    View in: PubMed
    Score: 0.798
  14. Decreasing the Cholesterol Burden in Heterozygous Familial Hypercholesterolemia Children by Dietary Plant Stanol Esters. Nutrients. 2018 Dec 01; 10(12).
    View in: PubMed
    Score: 0.798
  15. Depicting new pharmacological strategies for familial hypercholesterolaemia involving lipoprotein (a). Eur Heart J. 2017 12 21; 38(48):3555-3559.
    View in: PubMed
    Score: 0.747
  16. Older Familial Hypercholesterolemia Patients with COVID-19. Gerontology. 2021; 67(5):608-610.
    View in: PubMed
    Score: 0.234
  17. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev. 2017 07 07; 7:CD006401.
    View in: PubMed
    Score: 0.181
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.